HCA Healthcare reported second-quarter 2026 adjusted earnings per share of $7.59, beating the Zacks Consensus Estimate of $7.57 and rising 11% year over year. Revenues grew 8.7% to $20.2 billion, matching estimates, driven by a 2.7% increase in same-facility equivalent admissions and a 6.4% rise in revenue per equivalent admission. However, same-facility inpatient surgeries fell 2.3% and outpatient surgeries dropped 3.4%, while operating expenses climbed 9.8% to $16.2 billion. The company revised its full-year 2026 revenue guidance to a range of $77.0 billion to $79.5 billion, narrowed its adjusted EBITDA forecast to $15.4 billion to $16.1 billion, and lowered its diluted EPS outlook to $28.70 to $30.50.
Cencora Inc.
CVS Health CorpHCA Healthcare, Inc.beat Q2 earnings estimates on strong admissions and revenue growth
Charles River Laboratories